Syndyma is a monoclonal antibody used in the treatment of various cancers. It works by inhibiting angiogenesis, the process by which tumors develop new blood vessels to sustain their growth. Syndyma specifically binds to vascular endothelial growth factor (VEGF), a protein that promotes the formation of new blood vessels. By neutralizing VEGF, Syndyma starves tumors of their blood supply, inhibiting growth and progression. 

Indications:

• Colorectal Cancer: Advanced or metastatic stages, often in combination with chemotherapy.
• Non-Small Cell Lung Cancer (NSCLC): Metastatic cases, in combination with chemotherapy.
• Renal Cell Carcinoma (RCC): Advanced stages, often combined with interferon alfa.
• Cervical Cancer: Persistent, recurrent, or metastatic cases.
• Glioblastoma: As a second-line treatment.
• Ovarian Cancer: Platinum-resistant and recurrent forms.

Syndyma is a cornerstone in targeted cancer therapy due to its innovative approach to halting tumor growth. However, its use requires careful consideration of patient-specific factors and potential side effects. Collaborating with oncologists and monitoring during treatment ensures the best outcomes for patients.